Zycov-d Vaccine

Pharmaceutical company Zydus on Wednesday announced that it has started the supplies of its COVID-19 vaccine ZyCoV-D to the Government of India against their order from its newly commissioned state-of-the-art.

The Central Drugs Standard Organisation (CDSO) has approved the shelf life of COVID-19 vaccines Covaxin to 12 months, Covishield to nine months, and ZyCoV-D to six months from the date of manufacture, the Lok Sabha was informed on Friday.

Zydus Cadila's Covid vaccine ZyCoV-D will initially be used in 7 states, including Maharashtra, Tamil Nadu, UP and Bengal, which have been recommended to identify the districts with a high number of people who have not received a single dose yet.

The indigenously developed world's first DNA-based needle-free COVID-19 vaccine ZyCoV-D received emergency use authorisation from the drug regulator on August 20.

Zydus Cadila's ZyCov-D is the first vaccine cleared by India's drug regulator for inoculation of those aged 12 years and above

As many as 60 lakh doses of Zydus Cadila's three-dose COVID-19 vaccine ZyCoV-D are ready after production, said government sources.

The government today said Zydus Cadila's indigenously-developed needle-free Covid vaccine ZyCoV-D will be introduced in the nationwide vaccination drive very shortly and will be differentially priced than the jabs being used currently.

Drugmaker Shilpa Medicare Limited said on Friday it had agreed to produce Cadila Healthcare Ltd's three-dose COVID-19 vaccine.

The discussion on the pricing of Zydus Cadila's COVID-19 vaccine ZyCoV-D is underway, said Dr VK Paul, Member (Health) NITI Aayog on Tuesday.

ZyCoV-D is a needle-free vaccine administered using The PharmaJet a needle free applicator, which ensures painless intradermal vaccine delivery.

Zydus Cadila's Covid vaccine, ZyCoV-D, has received approval for emergency use authorization from the Drug Controller General of India

There will be more clarity on the prices of COVID-19 vaccine ZyCOV-D by next week, Zydus Group Managing Director Dr Sharvil Patel said today.

Zydus Cadila, whose Covid vaccine ZyCoV-D for adults and children aged 12 years and above got approval yesterday, said it hopes to produce one crore doses per month by October.

Zydus Cadila's Covid vaccine ZyCoV-D, meant for adults and children aged 12 years and above, was today approved for "restricted use in emergency situation" by the Central Drugs Standard Control Organisation (CDSCO).

India's drug regulator on Friday approved Zydus Cadila's three-dose COVID-19 DNA vaccine for emergency use in adults and children aged 12 years and above, bringing in the sixth vaccine authorised for use in the country.

Pharmaceutical company Zydus on Wednesday announced that it has started the supplies of its COVID-19 vaccine ZyCoV-D to the Government of India against their order from its newly commissioned state-of-the-art.

The Central Drugs Standard Organisation (CDSO) has approved the shelf life of COVID-19 vaccines Covaxin to 12 months, Covishield to nine months, and ZyCoV-D to six months from the date of manufacture, the Lok Sabha was informed on Friday.

Zydus Cadila's Covid vaccine ZyCoV-D will initially be used in 7 states, including Maharashtra, Tamil Nadu, UP and Bengal, which have been recommended to identify the districts with a high number of people who have not received a single dose yet.

The indigenously developed world's first DNA-based needle-free COVID-19 vaccine ZyCoV-D received emergency use authorisation from the drug regulator on August 20.

Zydus Cadila's ZyCov-D is the first vaccine cleared by India's drug regulator for inoculation of those aged 12 years and above

As many as 60 lakh doses of Zydus Cadila's three-dose COVID-19 vaccine ZyCoV-D are ready after production, said government sources.

The government today said Zydus Cadila's indigenously-developed needle-free Covid vaccine ZyCoV-D will be introduced in the nationwide vaccination drive very shortly and will be differentially priced than the jabs being used currently.

Drugmaker Shilpa Medicare Limited said on Friday it had agreed to produce Cadila Healthcare Ltd's three-dose COVID-19 vaccine.

The discussion on the pricing of Zydus Cadila's COVID-19 vaccine ZyCoV-D is underway, said Dr VK Paul, Member (Health) NITI Aayog on Tuesday.

ZyCoV-D is a needle-free vaccine administered using The PharmaJet a needle free applicator, which ensures painless intradermal vaccine delivery.

Zydus Cadila's Covid vaccine, ZyCoV-D, has received approval for emergency use authorization from the Drug Controller General of India

There will be more clarity on the prices of COVID-19 vaccine ZyCOV-D by next week, Zydus Group Managing Director Dr Sharvil Patel said today.

Zydus Cadila, whose Covid vaccine ZyCoV-D for adults and children aged 12 years and above got approval yesterday, said it hopes to produce one crore doses per month by October.

Zydus Cadila's Covid vaccine ZyCoV-D, meant for adults and children aged 12 years and above, was today approved for "restricted use in emergency situation" by the Central Drugs Standard Control Organisation (CDSCO).

India's drug regulator on Friday approved Zydus Cadila's three-dose COVID-19 DNA vaccine for emergency use in adults and children aged 12 years and above, bringing in the sixth vaccine authorised for use in the country.